Phase 2 Trial of Maximum Androgen Blockade (MAB) Dose Escalation From 50 mg to 150 mg Bicalutamide (Casodex) for Biochemical Failure in Prostate Cancer Patients
The study will be a national, multicentre, open-label, phase II trial. Patients who have a
rising PSA on MAB with bicalutamide 50 mg daily will be dose escalated to MAB with 150 mg
bicalutamide daily. Subjects will receive trial treatment for 12 months, or until disease
progression, unacceptable toxicity or withdrawal of consent. Open label treatment will be
offered thereafter if the subject demonstrates clinical benefit at the end of one year.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Doubling of PSA
one year
No
Laurence Klotz
Principal Investigator
Canadian Urology Research Consortium
Canada: Health Canada
D6876L00008
NCT00554086
November 2005
September 2010
Name | Location |
---|